Wegovy sales double but Novo Nordisk sees slower sales growth in 2025
Wegovy maker Novo Nordisk on Wednesday forecast sales would grow at a slower rate this year although the outlook was roughly in line with market expectations as the pace of ferocious demand for its wildly popular obesity drug Wegovy eases somewhat.
The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...
Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...
Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...
Novo Nordisk stock jumped Wednesday on better-than-expected fourth-quarter sales, helped by an Ozempic beat.
Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...
Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...
19hon MSN
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.
Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...
Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, one of Europe's largest listed companies, advanced nearly 3% in Denmark. Dig ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback